| ID | 56183 |
| JaLCDOI | |
| FullText URL | |
| Author |
Sekimizu, Masahiro
Department of Pediatrics, Nagoya Medical Center
Fujimoto, Junichiro
Department of Pathology, National Center for Child Health and Development
Takimoto, Tetsuya
Center for Clinical Research and Development, National Center for Child Health and Development
Tsurusawa, Masahito
Advanced Medical Research Center, Aichi Medical University
Horibe, Keizo
Department of Clinical Research Center
Sunami, Shosuke
Department of Pediatric Hematology Oncology, Japanese Red Cross Narita Hospital
|
| Abstract | Pediatric patients with lymphoblastic lymphoma are generally treated using the Berlin-Frankfurt-Munster (BFM) 90 protocol, which is the standard treatment strategy for pediatric acute lymphoblastic leukemia, and have a favorable outcome. However, this intense regimen includes high total doses of anthracycline and alkylating agents, and is known to cause late complications. We therefore planned a clinical trial to examine the efficacy and safety of a modified BFM regimen. We expect that this phase II, nationwide multicenter trial will help to establish an effective and safer standard therapy for stage I/II pediatric lymphoblastic lymphoma.
|
| Keywords | pediatrics
limited stage
lymphoblastic lymphoma
efficacy
safety
|
| Amo Type | Clinical Study Protocol
|
| Publication Title |
Acta Medica Okayama
|
| Published Date | 2018-08
|
| Volume | volume72
|
| Issue | issue4
|
| Publisher | Okayama University Medical School
|
| Start Page | 427
|
| End Page | 430
|
| ISSN | 0386-300X
|
| NCID | AA00508441
|
| Content Type |
Journal Article
|
| language |
English
|
| Copyright Holders | CopyrightⒸ 2018 by Okayama University Medical School
|
| File Version | publisher
|
| Refereed |
True
|
| PubMed ID |
